Cord Blood News Volume 2.46 | Dec 9 2010

Outcomes After Double Unit Unrelated Cord Blood Transplantation (UCBT) Compared with Single UCBT in Adults with Acute Leukemia in Remission. An Eurocord and ALWP Collaboration Study 
Double UCBT has extended the use of UCBT for patients otherwise not eligible for single UCBT and importantly is associated with better outcomes in adults patients with acute leukemia transplanted in early phase of the disease. [52nd American Society of Hematology Annual Meeting Abstract]
 

Interested in recruiting talented individuals? Post your career opportunities in Cord Blood News at no cost. Contact us at info@connexoncreative.com

 Follow us on Twitter! @Cord_Blood_News

Studies Highlight Important Role of Stem Cell Transplant Procedures for the Treatment of Blood Cancers
Results from four innovative studies help answer outstanding questions about stem cell transplant procedures in treating various hematologic malignancies. Research presented at the 52nd Annual Meeting of the American Society of Hematology reveals that the utilization of a double cord blood stem cell transplant is associated with better overall outcomes when used early in the treatment of acute leukemias. [American Society of Hematology Press Release]

		Need to expand CD34+ cells? StemSpan® serum-free expansion media are optimized for expanding hematopoietic stem and progenitor cells
		DOWNLOAD THE TECHNICAL BULLETIN

Analysis of Risk Factors Influencing Outcome in Children with Myelodysplastic Syndrome After Unrelated Cord Blood Transplantation
Data suggest that transplantation of mismatched umbilical cord blood graft is an acceptable alternative for children without a matched sibling or suitably matched unrelated adult donor. [Leukemia]

Lymphocyte Subset Reconstitution After Unrelated Cord Blood or Bone Marrow Transplantation in Children
Researchers report the post-transplant lymphocyte subset recovery of 226 children treated with unrelated cord blood transplant (n = 112) or unrelated bone marrow transplant (n = 114) for malignant or non-malignant diseases. [Br J Haematol]

Storage Characteristics of Cord Blood Progenitor Cells: Report of a Multicenter Study by the Cellular Therapies Team of the Biomedical Excellence for Safer Transfusion (BEST) Collaborative
Cord blood hematopoietic progenitor cell collections maintained at 4°C retained higher total nucleated cell counts, mononuclear cell counts, and CD45+ cell viability over a 72- to 96-hour storage period. [Transfusion]

Human Umbilical Cord Stromal Stem Cell Express CD10 and Exert Contractile Properties
Umbilical cord stromal stem cells are mesenchymal stem cells that reside in the perivascular area of Wharton’s jelly and are phenotypically and functionally related to myofibroblasts. [Placenta]

T-Lymphocyte Recovery and Function After Cord Blood Transplantation
Findings offer a major step in fulfilling critical biological requirements to quickly generate a cellular product ex vivo, using a negligible fraction of a cord blood graft that provides a flexible adoptive immunotherapy platform for both children and adults. [Immunol Res]

Reduced Intensity Conditioning Regimen Prior to Unrelated Cord Blood Transplantation In Patients with Acute Myeloid Leukemia : Preliminary Analysis of a Prospective Phase II Multicentric Trial on Behalf of Societe Française De Greffe De Moelle Osseuse Et Therapie Cellulaire (SFGM-TC) and Eurocord
To evaluate reduced intensity conditioning regimen-unrelated cord blood transplantation in patients with acute myeloid leukemia (AML), researchers conducted a prospective Phase II multicentric trial in France, whose primary objective was to show a reduction in non-relapse mortality from 40% (based on registry data) to 20%. [52nd American Society of Hematology Annual Meeting Abstract]

Cephalon and Mesoblast Enter Into Strategic Alliance to Develop and Commercialize Novel Therapeutic Products for Regenerative Medicine
Cephalon, Inc. and Mesoblast Limited announced they have entered into a strategic alliance to develop and commercialize novel adult Mesenchymal Precursor Stem Cell therapeutics for degenerative conditions of the cardiovascular and central nervous systems. The alliance also extends to products for augmenting hematopoietic stem cell transplantation in cancer patients. [Cephalon, Inc. Press Release]
 
Cytheris Announces Interim Results of Phase I Study Showing That Recombinant Human Interleukin-7 (CYT107) Promotes T-Cell Recovery Following T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation
Cytheris SA announced interim results from a Phase I clinical trial of its investigational drug candidate, recombinant human Interleukin-7 (CYT107), in the treatment of post-transplant patients with T-cell depleted bone marrow or peripheral blood stem cell transplants. [Cytheris SA Press Release]

ZEVALIN Data as Preparatory Regimen Presented Prior to Autologous and Allogeneic Stem Cell Transplantation in the Treatment of Non-Hodgkin’s Lymphoma
Spectrum Pharmaceuticals, Inc. announced the presentation of ZEVALIN data as a preparatory or conditioning regimen prior to both allogeneic and autologous stem cell transplantation at the 52nd American Society of Hematology Annual Meeting in Orlando, Florida. [Spectrum Pharmaceuticals, Inc. Press Release]

Cord Blood America Would Triple Size with Mexico Stem Cell Storage Acquisition
Cord Blood America, Inc. announced that it has signed a letter of intent to purchase Cryo-Cell Mexico, which is Mexico’s largest stem cell storage company. [Cord Blood America, Inc. Press Release]

GeneCell International Opens Miami-Based Headquarters, First and Only Cord Blood Processing and Cryogenic Storage Laboratory in Miami
GeneCell International announced the opening of its new, Miami-based corporate headquarters and laboratory. [Business Wire]

House Approves Flat 2011 Budget for Most Science Agencies
The three federal agencies that support the vast majority of academic research would receive no more money in 2011 than in 2010 under a spending bill that narrowly passed the House of Representatives. [House of Representatives, United States]

National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)
 
European Medicines Agency (European Union)
 
Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

Inaugural Theranostics for Personalised Medicine
May 18-19, 2011
London, United Kingdom
 
13th Annual C21 BioVentures
May 24-26, 2011
Napa, United States

NEW 9th Annual International Umbilical Cord Blood Transplantation Symposium
June 9-11, 2011
San Francisco, United States

NEW International Society for Stem Cell Research (ISSCR) 9th Annual Meeting
June 15-18, 2011
Toronto, Canada

Visit our events page to stay up to date with the latest events in the cell, gene and immunotherapy community.

Visit here to post your career opportunities.

Have we missed an important article or publication in Cord Blood News? Click here to submit!

Comments or Suggestions? Email info@connexoncreative.com with your feedback.